PETS / PetMed Express, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2025 PetMed Express, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2025 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fil

SEPARATION AGREEMENT

SEPARATION AGREEMENT THIS SEPARATION AGREEMENT (this “Agreement”) is dated as of August 11, 2025 (the “Effective Date”), by and between Sandra Campos, an individual (“Executive”), and PETMED EXPRESS, INC.

PetMed Express, Inc. Announces Management Changes

EXHIBIT 99.1 PetMed Express, Inc. Announces Management Changes Delray Beach, Florida, August 12, 2025, PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced that its Chief Executive Officer, Sandra Campos, and Chief Financial Officer, Robyn D’Elia, have resigned from their positions and employment with the Company. As part of the leadership

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2025 PetMed Express, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2025 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fil

SEPARATION AGREEMENT

SEPARATION AGREEMENT THIS SEPARATION AGREEMENT (this “Agreement”) is dated as of August 11, 2025 (the “Effective Date”), by and between Robyn D’Elia, an individual (“Executive”), and PETMED EXPRESS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on For

RESIGNATION LETTER

RESIGNATION LETTER July 24, 2025 The Board of Directors, Inc. PetMed Express, Inc. 420 South Congress Avenue Delray Beach, Florida 33445 Ladies and Gentlemen: Please accept this letter as my formal resignation from the board of directors of PetMed Express, Inc. (the “Company”) effective immediately. Please note that my resignation is not because of any disagreement with the Company on any matter r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2025 PetMed Express, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2025 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2025 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File N

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Exhibit 99.1 PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K Del Ray Beach, FL, July 3, 2025 — PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS) received on July 2, 2025, an expected notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Annual Report on Form

PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results and Form 10-K Filing

Exhibit 99.1 PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results and Form 10-K Filing Delray Beach, Florida, July 1, 2025, PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today provided an update on the status of its fourth quarter and FY 2025 results and 10-K filing. On June 16, 2025, the Company filed a Form 12b-25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2025 PetMed Express, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2025 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File N

PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25

Exhibit 99.1 PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25 Delray Beach, Florida, June 16, 2025, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced preliminary fourth quarter and fiscal year 2025 results and filed Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 PETMED EXPRESS, INC. (Exact Name of Registrant as Specified in its Charter) Florida 000-28827 65-0680967 (State or Other Jurisdiction (Commission (IRS Employer of Incorp

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 9, 2025 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity Third independent director to join the Board

EXHIBIT 99.1 PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity Third independent director to join the Board since 2024 Longtime board member and former Chairman Dr. Gian Fulgoni will retire DELRAY BEACH, Fla., April 9, 2025 (GLOBE NEWSWIRE) - Pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 o TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2025 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission F

PetMeds® Announces Third Quarter Fiscal 2025 Financial Results

Exhibit 99.1 PetMeds® Announces Third Quarter Fiscal 2025 Financial Results Delray Beach, Florida, February 10, 2025, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its third quarter ended December 31, 2024. Third Quarter Fiscal 2025 Financial Highlights •Net sales of $53.0 million. •Gross margin rate of 28.1%, an increase

Articles of Amendment to the Amended and Restated Articles of Incorporation, dated December 3, 2024 (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on December 3, 2024).

ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION OF PETMED EXPRESS, INC.

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission

Rights Agreement, dated December 3, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as rights agent (incorporated by reference to Exhibit 4.1 to our Form 8-K/A filed December 18, 2024).

Execution Version PETMED EXPRESS, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY as Rights Agent RIGHTS AGREEMENT Dated as of December 3, 2024 4934-2276-9410.1 TABLE OF CONTENTS Page Number Section 1. Definitions. 1 Section 2. Appointment of Rights Agent. 8 Section 3. Issue of Right Certificates. 8 Section 4. Form of Right Certificates. 10 Section 5. Countersignature and Registration. 11 Sect

Articles of Amendment to the Amended and Restated Articles of Incorporation, dated December 3, 2024.

Privileged & Confidential ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION OF PETMED EXPRESS, INC.

Articles of Amendment to the Amended and Restated Articles of Incorporation, dated December 3, 2024 (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on December 3, 2024).

EX-3.1 5 pets-articlesofamendmentto.htm EX-3.1 Privileged & Confidential ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION OF PETMED EXPRESS, INC. (P96000010098) DESIGNATING SERIES A JUNIOR PARTICIPATING PREFERRED STOCK PETMED EXPRESS, INC., a Florida corporation (the “Corporation”), in accordance with the provisions of Section 607.0602 of the Florida Business Corporation

Rights Agreement, dated December 3, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as rights agent (which includes the Form of Right Certificate as Exhibit B thereto) (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on December 3).

Privileged & Confidential PETMED EXPRESS, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY as Rights Agent RIGHTS AGREEMENT Dated as of December 3, 2024 4872-4688-7820.9 TABLE OF CONTENTS Page Number Section 1. Definitions. 1 Section 2. Appointment of Rights Agent. 8 Section 3. Issue of Right Certificates. 8 Section 4. Form of Right Certificates. 10 Section 5. Countersignature and Registration.

Rights Agreement, dated December 3, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as rights agent (which includes the Form of Rights Certificate as

Privileged & Confidential PETMED EXPRESS, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY as Rights Agent RIGHTS AGREEMENT Dated as of December 3, 2024 4872-4688-7820.9 TABLE OF CONTENTS Page Number Section 1. Definitions. 1 Section 2. Appointment of Rights Agent. 8 Section 3. Issue of Right Certificates. 8 Section 4. Form of Right Certificates. 10 Section 5. Countersignature and Registration.

PetMeds® Adopts Limited Duration Shareholder Rights Plan

EXHIBIT 99.1 PetMeds® Adopts Limited Duration Shareholder Rights Plan Delray Beach, Florida – December 3, 2024 - PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) (“PetMeds” or the “Company”), today announced that its Board of Directors (the “Board”) has adopted a limited duration shareholder rights plan to protect the best interests of all PetMeds shareholders (the “

FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 PETMED EXPRESS, INC.

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

PETS / PetMed Express, Inc. / HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC Passive Investment

SC 13G 1 hotchkiswiley-pets093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PETMED EXPRESS INC (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 716382106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED

(incorporated by reference to Exhibit 3.3 to our Form 10-Q for the quarter ended September 30, 2024, filed November 7, 2024).

Exhibit 3.3 THIRD AMENDED AND RESTATED BYLAWS OF PETMED EXPRESS, INC. (A FLORIDA CORPORATION) AS LAST AMENDED ON NOVEMBER 6, 2024 4872-2926-5138.9 TABLE OF CONTENTS Page Section 1.1 Definitions 1 Article 2 Offices 1 Section 2.1 Principal and Business Offices 1 Section 2.2 Registered Office 1 Article 3 Shareholders 2 Section 3.1 Annual Meeting 2 Section 3.2 Special Meetings 2 Section 3.3 Place of S

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

PetMeds® Announces Second Quarter Fiscal 2025 Financial Results

Exhibit 99.1 PetMeds® Announces Second Quarter Fiscal 2025 Financial Results Delray Beach, Florida, November 6, 2024, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2024. Second Quarter Fiscal 2025 Financial Highlights •Net sales of $59.6 million. •Gross margin of 29.1%, an increase of

PETS / PetMed Express, Inc. / NINA CAPITAL HOLDINGS INC. - SCHEDULE 13G Passive Investment

SC 13G 1 ea0217351-13gninapetmed.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to §240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to §240.13d-2 Under the Securities Exchange Act of 1934 Petmed Express, Inc. (Name of Issuer) Common Stock, par value $.001 pe

Form of Performance Stock Unit Award under 2024

Exhibit 10.1.2 PETMED EXPRESS, INC. 2024 INDUCEMENT INCENTIVE PLAN PERFORMANCE STOCK UNIT AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award of Performance Stock Units (this “Award”) of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Inducement Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditions s

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission

Form of Restricted Stock Award under 2024 Inducement Incentive Plan.

Exhibit 99.1.3 PETMED EXPRESS, INC. 2024 INDUCEMENT INCENTIVE PLAN RESTRICTED STOCK AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award (this “Award”) of shares of common stock of PetMed Express, Inc. (the “Company”) constituting a Restricted Stock Award under the PetMed Express, Inc. 2024 Inducement Incentive Plan (the “Plan”), effective as of the Grant Date,

Form of Restricted Stock Unit Award under 2024

Exhibit 10.1.1 PETMED EXPRESS, INC. 2024 INDUCEMENT INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award of Restricted Stock Units (this “Award”) of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Inducement Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditions set forth below. Ca

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933

As filed with the Securities and Exchange Commission on September 27, 2024 Registration No.

Form of Restricted Stock Award under 2024

Exhibit 10.1.3 PETMED EXPRESS, INC. 2024 INDUCEMENT INCENTIVE PLAN RESTRICTED STOCK AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award (this “Award”) of shares of common stock of PetMed Express, Inc. (the “Company”) constituting a Restricted Stock Award under the PetMed Express, Inc. 2024 Inducement Incentive Plan (the “Plan”), effective as of the Grant Date,

, Inc. 2024 Inducement Incentive Plan (incorporated by reference to Exhibit 10.1 to our Form 8-K filed September 27, 2024).

PETMED EXPRESS, INC. 2024 INDUCEMENT INCENTIVE PLAN 1.Purpose; Effective Date. (a)Purpose. The PetMed Express, Inc. 2024 Inducement Incentive Plan (the “Plan”) has two complementary purposes: (i) to attract and retain outstanding individuals to serve as employees and (ii) to increase stockholder value. The Plan will provide participants incentives to increase stockholder value by offering the oppo

Form of Restricted Stock Unit Award under 2024 Inducement Incentive Plan.

Exhibit 99.1.1 PETMED EXPRESS, INC. 2024 INDUCEMENT INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award of Restricted Stock Units (this “Award”) of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Inducement Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditions set forth below. Ca

Calculation of Registration Fee

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) PetMed Express, Inc.

Form of Performance Stock Unit Award under 2024 Inducement Incentive Plan.

Exhibit 99.1.2 PETMED EXPRESS, INC. 2024 INDUCEMENT INCENTIVE PLAN PERFORMANCE STOCK UNIT AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award of Performance Stock Units (this “Award”) of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Inducement Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditions s

Form of Stock Option Award under the 2024

Exhibit 10.1.4 PETMED EXPRESS, INC. 2024 INDUCEMENT INCENTIVE PLAN STOCK OPTION AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an option (this “Option”) to purchase shares of the common stock of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Inducement Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditio

PetMed Express, Inc. 2024 Inducement Incentive Plan.

PETMED EXPRESS, INC. 2024 INDUCEMENT INCENTIVE PLAN 1.Purpose; Effective Date. (a)Purpose. The PetMed Express, Inc. 2024 Inducement Incentive Plan (the “Plan”) has two complementary purposes: (i) to attract and retain outstanding individuals to serve as employees and (ii) to increase stockholder value. The Plan will provide participants incentives to increase stockholder value by offering the oppo

Form of Stock Option Award under 2024 Inducement Incentive Plan.

Exhibit 99.1.4 PETMED EXPRESS, INC. 2024 INDUCEMENT INCENTIVE PLAN STOCK OPTION AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an option (this “Option”) to purchase shares of the common stock of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Inducement Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditio

PetMed Express, Inc. Announces Appointment of Robyn D’Elia as Chief Financial Officer D’Elia Brings More than 25 Years of Strategic Finance and Retail Leadership Experience to PetMeds

EXHIBIT 99.1 PetMed Express, Inc. Announces Appointment of Robyn D’Elia as Chief Financial Officer D’Elia Brings More than 25 Years of Strategic Finance and Retail Leadership Experience to PetMeds DELRAY BEACH, Fla., September 12, 2024 (GLOBE NEWSWIRE) – PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the "Company") today announced the appointment of retail and e

Executive Employment Agreement by and between PetMed Express, Inc. and Robyn D’Elia

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (hereinafter “Agreement”) is made and entered into effective as of September 16, 2024, by and between PETMED EXPRESS, INC., a Florida corporation (“Company”), and ROBYN D’ELIA, an individual residing in the State of New Jersey (hereinafter called “Executive”). RECITALS WHEREAS, Company desires to retain the services of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2024 PetMed Express

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933

As filed with the Securities and Exchange Commission on August 8, 2024 Registration No.

under 2024 Omnibus Incentive Plan

Exhibit 99.1.4 PETMED EXPRESS, INC. 2024 OMNIBUS INCENTIVE PLAN STOCK OPTION AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an option (this “Option”) to purchase shares of the common stock of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Omnibus Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditions set

2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1.4 to our Form 8-K filed August 8, 2024).

Exhibit 10.1.4 PETMED EXPRESS, INC. 2024 OMNIBUS INCENTIVE PLAN STOCK OPTION AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an option (this “Option”) to purchase shares of the common stock of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Omnibus Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditions set

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

under 2024 Omnibus Incentive Plan.

Exhibit 10.1.2 PETMED EXPRESS, INC. 2024 OMNIBUS INCENTIVE PLAN PERFORMANCE STOCK UNIT AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award of Performance Stock Units (this “Award”) of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Omnibus Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditions set for

Non-Employee Director Compensation Program, revised as of August 8, 2024.

Exhibit 10.2 PETMED EXPRESS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (Revised as of August 8, 2024) Non-employee members of the board of directors (the “Board”) of PetMed Express, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall b

Form of Restricted Stock Unit Award under 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1.1 to our Form 8-K filed August 8, 2024).

Exhibit 10.1.1 PETMED EXPRESS, INC. 2024 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award of Restricted Stock Units (this “Award”) of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Omnibus Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditions set forth

Form of Restricted Stock Award under 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1.3 to our Form

Exhibit 10.1.3 PETMED EXPRESS, INC. 2024 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award (this “Award”) of shares of common stock of PetMed Express, Inc. (the “Company”) constituting a Restricted Stock Award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan (the “Plan”), effective as of the Grant Date, with t

. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to our Form 8-K filed August 8, 2024).

PETMED EXPRESS, INC. 2024 OMNIBUS INCENTIVE PLAN 1.Purpose; Effective Date; Effect on Prior Plans. (a)Purpose. The PetMed Express, Inc. 2024 Omnibus Incentive Plan (the “Plan”) has two complementary purposes: (i) to attract and retain outstanding individuals to serve as officers, directors, employees, and consultants, and (ii) to increase stockholder value. The Plan will provide participants incen

2024 Omnibus Incentive Plan.

Exhibit 99.1.3 PETMED EXPRESS, INC. 2024 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award (this “Award”) of shares of common stock of PetMed Express, Inc. (the “Company”) constituting a Restricted Stock Award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan (the “Plan”), effective as of the Grant Date, with t

Calculation of Registration Fee

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) PetMed Express, Inc.

PetMed Express, Inc. 2024 Omnibus Incentive Plan.

Exhibit 99.1 PETMED EXPRESS, INC. 2024 OMNIBUS INCENTIVE PLAN 1.Purpose; Effective Date; Effect on Prior Plans. (a)Purpose. The PetMed Express, Inc. 2024 Omnibus Incentive Plan (the “Plan”) has two complementary purposes: (i) to attract and retain outstanding individuals to serve as officers, directors, employees, and consultants, and (ii) to increase stockholder value. The Plan will provide parti

under 2024 Omnibus Incentive Plan.

Exhibit 99.1.1 PETMED EXPRESS, INC. 2024 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award of Restricted Stock Units (this “Award”) of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Omnibus Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditions set forth

Form of Performance Stock Unit

Exhibit 99.1.2 PETMED EXPRESS, INC. 2024 OMNIBUS INCENTIVE PLAN PERFORMANCE STOCK UNIT AWARD [PARTICIPANTID] [FIRSTNAME] [LASTNAME] Dear [NAME]: You have been granted an award of Performance Stock Units (this “Award”) of PetMed Express, Inc. (the “Company”) under the PetMed Express, Inc. 2024 Omnibus Incentive Plan (the “Plan”), effective as of the Grant Date, with the terms and conditions set for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED EXPR

PetMeds® Announces Fiscal 2025 First Quarter Financial Results Net Income for first quarter fiscal 2025 was $3.8 million or $0.18 diluted earnings per share

Exhibit 99.1 PetMeds® Announces Fiscal 2025 First Quarter Financial Results Net Income for first quarter fiscal 2025 was $3.8 million or $0.18 diluted earnings per share Delray Beach, Florida, August 6, 2024, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2024. Quarterly Highlights for Q1, F

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PetMed Express, Inc. Announces Appointment of Doug Krulik as Chief Accounting Officer Krulik Brings More than 20 Years of Leadership Experience in Finance and Accounting

EXHIBIT 99.1 PetMed Express, Inc. Announces Appointment of Doug Krulik as Chief Accounting Officer Krulik Brings More than 20 Years of Leadership Experience in Finance and Accounting DELRAY BEACH, Fla., August 5, 2024 (GLOBE NEWSWIRE) - PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the "Company") today announced the appointment of Doug Krulik as Chief Accountin

Doug Krulik and PetMed Express, Inc. (incorporated by reference to Exhibit 10.1 to our Form 8-K filed August 5, 2024).

Exhibit 10.1 DELIVERED ELECTRONICALLY July 22, 2024 Douglas Krulik RE: Offer of Employment Dear Mr. Krulik: We appreciate your interest in PetMed Express, Inc. (the “Company”). On behalf of the Company, I am pleased to present you with this offer of employment. We are offering you the full-time position of Title of Chief Accounting Officer, reporting to Sandra Campos, President & Chief Executive O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) De

PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors Visionary founder and investor brings decades of experience building and scaling digital consumer brands

EXHIBIT 99.1 PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors Visionary founder and investor brings decades of experience building and scaling digital consumer brands DELRAY BEACH, Fla., June 24, 2024 (GLOBE NEWSWIRE) - PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the "Company") today announced the appointment of Leah Solivan to

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Defi

Executive Compensation Recovery Policy

Exhibit 97.1 PetMed Express, Inc. EXECUTIVE COMPENSATION RECOVERY POLICY (Effective October 25, 2023) This Executive Compensation Recovery Policy (“Policy”) covers Covered Officers of PetMed Express, Inc. (collectively with its subsidiaries, “PetMeds”) and explains when PetMeds will be required or authorized, as applicable, to seek recovery of Incentive Compensation awarded or paid to Covered Offi

Description of Securities.*

Exhibit 4.2 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of the common stock, $0.001 par value per share (the “Common Stock”), of PetMed Express, Inc., a Florida corporation (the “Company”), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28827 PETMED EXPRESS, INC. (Exact n

Statement of Policy Regarding Insider Trading

Exhibit 19.1 Statement of Policy Regarding Insider Trading (Amended and Restated Effective July 28, 2022) To: All directors, officers and employees of and consultants to PetMed Express, Inc. and its subsidiaries (collectively, the “Company”) Introduction The purpose of this memorandum is to remind you of your obligation as a director, officer or employee of, or consultant to, the Company to treat

Subsidiaries of Registrant*

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT (1) PETMED EXPRESS, INC. (as of March 31, 2024) Subsidiaries Wholly-Owned by PetMed Express, Inc. Entity Name State of Incorporation or Organization Southeastern Veterinary Exports, Inc. Florida Global Veterinary Supply, Inc. Florida 420 South Congress Avenue, LLC Florida PetCareRx, Inc. New York PetMeds Insurance Services, LLC Florida Indirectly Owned S

PetMeds® Announces Its Fourth Quarter and Fiscal Year End Financial Results

Exhibit 99.1 PetMeds® Announces Its Fourth Quarter and Fiscal Year End Financial Results Delray Beach, Florida, June 11, 2024, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its fourth quarter and fiscal year ended March 31, 2024. Quarterly Highlights •Net sales for the quarter ended March 31, 2024, were $66.5 million, comp

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File N

Transition and Separation Agreement, dated May 31, 2024, between the Company and Christine Chambers.

EXHIBIT 10.1 TRANSITION AND SEPARATION AGREEMENT THIS TRANSITION AND SEPARATION AGREEMENT (this “Agreement”) is dated as of May 31, 2024 (the “Effective Date”), by and between CHRISTINE CHAMBERS, an individual whose address is 7723 Tomlinson Avenue, Cabin John, MD 20818 (“Executive”), and PETMED EXPRESS, INC., a Florida corporation whose principal place of business is located at 420 South Congress

PetMed Express, Inc. Announces Appointment of Justin Mennen to Board of Directors Veteran technology executive brings decades of experience leading digital transformations across large-scale global enterprises

EXHIBIT 99.1 PetMed Express, Inc. Announces Appointment of Justin Mennen to Board of Directors Veteran technology executive brings decades of experience leading digital transformations across large-scale global enterprises DELRAY BEACH, Fla., May 20, 2024 (GLOBE NEWSWIRE) - PetMed Express, Inc., parent company of PetMeds and PetCareRx, (Nasdaq: PETS) (the "Company") today announced the appointment

Non-Employee Director Compensation Program, effective May

EXHIBIT 10.1 PETMED EXPRESS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (Effective May 19, 2024) Non-employee members of the board of directors (the “Board”) of PetMed Express, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File N

Executive Employment Agreement, dated April 29, 2024, between the Company and Sandra Campos

EXHIBIT 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (hereinafter “Agreement”) is made and entered into effective as of April 29, 2024, by and between PETMED EXPRESS, INC., a Florida corporation (“Company”), and SANDRA CAMPOS, an individual residing in the State of New York (hereinafter called “Executive”). RECITALS WHEREAS, Company desires to retain the services of Exec

orporated by reference to Exhibit 10.1 to our Form 8-K filed on April 29,

EXHIBIT 10.1 TRANSITION AND SEPARATION AGREEMENT THIS TRANSITION AND SEPARATION AGREEMENT (this “Agreement”) is dated as of April 29, 2024 (the “Effective Date”), by and between MATHEW HULETT, an individual whose address is 7044 54th Ave NE, Seattle, WA 98115 (“Executive”), and PETMED EXPRESS, INC., a Florida corporation whose principal place of business is located at 420 South Congress Avenue, De

PetMed Express, Inc. Names Sandra Campos as new Chief Executive Officer and President

EXHIBIT 99.1 PetMed Express, Inc. Names Sandra Campos as new Chief Executive Officer and President •Sandra Campos, retail E-commerce veteran, becomes CEO and President, effective immediately, after spending the past year serving on the Company’s Board of Directors and remains on the Board •Ms. Campos brings a deep understanding of the industry and company; focusing on unlocking shareholder value t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2024 PetMed Express, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 o TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED

PetMeds® Announces Fiscal 2024 Third Quarter Financial Results and Completion of Financial Restatement. Fiscal 2024 3Q Revenue of $65.3 million, an 11% increase compared to last year including PetCareRx results. AutoShip & Save and PetPlus Membership

Exhibit 99.1 PetMeds® Announces Fiscal 2024 Third Quarter Financial Results and Completion of Financial Restatement. Fiscal 2024 3Q Revenue of $65.3 million, an 11% increase compared to last year including PetCareRx results. AutoShip & Save and PetPlus Membership, 52% of total revenue, up from 42% at the same time last year. Strong balance sheet with $49.4 million of cash The Company is now curren

PetMeds® Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Exhibit 99.1 PetMeds® Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q DELRAY BEACH, Fla, Feb 15, 2024 – PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS) received on February 13, 2024, a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-Q with the SE

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission F

PETS / PetMed Express, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01691-petmedexpressinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: PetMed Express Inc Title of Class of Securities: Common Stock CUSIP Number: 716382106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Per

PetMeds® Announces Selected Preliminary Third Quarter Financial Results Company to Restate Certain Previously Issued Financial Statements Due to Correction of Errors in Accounting for Tax-Related Entries; Filing of Form 10-Q to be Delayed.

Exhibit 99.1 PetMeds® Announces Selected Preliminary Third Quarter Financial Results Company to Restate Certain Previously Issued Financial Statements Due to Correction of Errors in Accounting for Tax-Related Entries; Filing of Form 10-Q to be Delayed. Delray Beach, Florida, February 8, 2024 – PetMed Express, Inc. (NASDAQ: PETS) (“PetMeds” or the “Company”), Your Trusted Pet Health ExpertTM, today

Regulation FD Disclosure, Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

PETS / PetMed Express, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us7163821066012524.txt us7163821066012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) PETMED EXPRESS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 716382106 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2024 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED

PetMeds® Announces Its Second Quarter Financial Results

Exhibit 99.1 PetMeds® Announces Its Second Quarter Financial Results Delray Beach, Florida, October 30, 2023, PetMed Express, Inc. (NASDAQ: PETS)(“PetMeds” or “Company”), Your Trusted Pet Health ExpertTM, today announced its financial results for its second quarter ended September 30, 2023. Quarterly Highlights •Net sales for the quarter ended September 30, 2023, were $71.0 million, compared to $6

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933

As filed with the Securities and Exchange Commission on August 30, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933

As filed with the Securities and Exchange Commission on August 30, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933

As filed with the Securities and Exchange Commission on August 28, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933

As filed with the Securities and Exchange Commission on August 28, 2023 Registration No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED EXPR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2023 PetMed Express, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PetMeds® Announces Its First Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share

Exhibit 99.1 PetMeds® Announces Its First Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share Delray Beach, Florida, July 31, 2023, PetMed Express, Inc. (NASDAQ: PETS)(“PetMeds” or “Company”), Your Trusted Pet Health ExpertTM, today announced its financial results for its first quarter ended June 30, 2023. Quarterly Highlights •Net sales for the quarter ended June 30, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Defi

2015 Outside Director Equity Compensation Plan (as amended and restated)

Exhibit 10.5 PETMED EXPRESS, INC. 2015 OUTSIDE DIRECTOR EQUITY COMPENSATION PLAN (amending and restating the PetMed Express, Inc. 2015 Outside Director Equity Compensation Restricted Stock Plan) 1. PURPOSE OF PLAN The PetMed Express, Inc. 2015 Outside Director Equity Compensation Plan, f/k/a the 2015 Outside Director Equity Compensation Restricted Stock Plan (the “2015 Plan”), is established by Pe

Form of Performance Stock Unit Agreement under 2022 Employee Equity Compensation Plan

Exhibit 10.4 PERFORMANCE STOCK UNIT AGREEMENT PURSUANT TO PETMED EXPRESS, INC. 2022 EMPLOYEE EQUITY COMPENSATION PLAN THIS PERFORMANCE STOCK UNIT AGREEMENT (“Agreement”) is made this day of , 202 by and between (the "Participant") and PetMed Express, Inc., a Florida corporation, on behalf of itself, its subsidiaries and affiliates (collectively, the "Company") pursuant to the Company's 2022 Employ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 PetMed Express, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PetMed Express, Inc. 2015 Outside Director Equity Compensation Plan (as amended and restated), marked to show amendments made to the 2015 Outside Director Equity Compensation Restricted Stock Plan

Exhibit 10.6 PETMED EXPRESS, INC. 2015 OUTSIDE DIRECTOR EQUITY COMPENSATION RESTRICTED STOCK PLAN PLAN (amending and restating the PetMed Express, Inc. 2015 Outside Director Equity Compensation Restricted Stock Plan) 1. PURPOSE OF PLAN The PetMed Express, Inc. 2015 Outside Director Equity Compensation Plan, f/k/a the 2015 Outside Director Equity Compensation Restricted Stock Award Plan (the “2015

2022 Employee Equity Compensation Plan (as amended and restated)

Exhibit 10.1 PETMED EXPRESS, INC. 2022 EMPLOYEE EQUITY COMPENSATION PLAN (amending and restating the PetMed Express, Inc. 2022 Employee Equity Compensation Restricted Stock Plan) 1. PURPOSE OF PLAN The purpose of the PetMed Express, Inc. 2022 Employee Equity Compensation Plan f/k/a the 2022 Employee Equity Compensation Restricted Stock Plan (the "2022 Plan"), which is being established by PetMed E

Form of Restricted Stock Unit Agreement under 2022 Employee Equity Compensation Plan

Exhibit 10.3 RESTRICTED STOCK UNIT AGREEMENT PURSUANT TO PETMED EXPRESS, INC. 2022 EMPLOYEE EQUITY COMPENSATION PLAN THIS RESTRICTED STOCK UNIT AGREEMENT (“Agreement”) is made this day of , 202 by and between (the "Participant") and PetMed Express, Inc., a Florida corporation, on behalf of itself, its subsidiaries and affiliates (collectively, the "Company") pursuant to the Company's 2022 Employee

Form of Restricted Stock Unit Agreement under 2015 Outside Director Equity Compensation Plan

Exhibit 10.7 RESTRICTED STOCK UNIT AGREEMENT PURSUANT TO PETMED EXPRESS, INC. 2015 DIRECTOR EQUITY COMPENSATION PLAN THIS RESTRICTED STOCK UNIT AGREEMENT (“Agreement”) is made this day of , 202 by and between (the "Director") and PetMed Express, Inc., a Florida corporation, on behalf of itself, its subsidiaries and affiliates (collectively, the "Company") pursuant to the Company's 2015 Director Eq

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(

PetMed Express, Inc. 2022 Employee Equity Compensation Plan (as amended and restated), marked to show amendments made to the 2022 Employee Equity Compensation Restricted Stock Plan

Exhibit 10.2 PETMED EXPRESS, INC. 2022 EMPLOYEE EQUITY COMPENSATION RESTRICTED STOCK PLAN (amending and restating the PetMed Express, Inc. 2022 Employee Equity Compensation Restricted Stock Plan) 1. PURPOSE OF PLAN The purpose of the PetMed Express, Inc. 2022 Employee Equity Compensation Plan f/k/a the 2022 Employee Equity Compensation Restricted Stock Plan (the "2022 Plan"), which is being establ

PETMED EXPRESS, INC. QUARTER AND YEAR ENDED MARCH 31, 2023 CONFERENCE CALL TRANSCRIPT MAY 22, 2023 AT 4:30 P.M. ET

Exhibit 99.1 PETMED EXPRESS, INC. QUARTER AND YEAR ENDED MARCH 31, 2023 CONFERENCE CALL TRANSCRIPT MAY 22, 2023 AT 4:30 P.M. ET C O R P O R A T E P A R T I C I P A N T S Brian M. Prenoveau, CFAMZ Group Matt Hulett, Chief Executive Officer and President Christine Chambers, Chief Financial Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Corey Grady, Jefferies Anthony Lebiedzinski, Sidoti

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File N

Subsidiaries of Registrant*

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT (1) PETMED EXPRESS, INC. (as of March 31, 2023) Subsidiaries Wholly-Owned by PetMed Express, Inc. (“Company”) Entity Name State of Incorporation or Organization Southeastern Veterinary Exports, Inc. Florida Global Veterinary Supply, Inc. Florida 420 South Congress Avenue, LLC Florida Harry Merger Sub, Inc. New York PetMeds Insurance Services, LLC Florida

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28827 PETMED EXPR

Form of Restricted Stock Agreement used for grants of restricted stock under the 2022 Employee Equity Compensation Restricted Stock Plan.

Exhibit 10.7.1 RESTRICTED STOCK AGREEMENT PURSUANT TO PETMED EXPRESS, INC. 2022 EMPLOYEE EQUITY COMPENSATION RESTRICTED STOCK PLAN THIS RESTRICTED STOCK AGREEMENT (“Agreement”) is made this day of , 202 by and between (the "Participant") and PetMed Express, Inc., a Florida corporation, on behalf of itself, its subsidiaries and affiliates (collectively, the "Company") pursuant to the Company's 2022

Description of Securities.*

Exhibit 4.2 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of the common stock, $0.001 par value per share (the “Common Stock”), of PetMed Express, Inc., a Florida corporation (the “Company”), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2023 PetMed Express, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File N

PetMeds® Announces Its Fourth Quarter and Fiscal Year End Financial Results and Declares a Quarterly Dividend of $0.30 Per Share

Exhibit 99.1 PetMeds® Announces Its Fourth Quarter and Fiscal Year End Financial Results and Declares a Quarterly Dividend of $0.30 Per Share Delray Beach, Florida, May 22, 2023, PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health ExpertTM, today announced its financial results for its fourth quarter and fiscal year ended March 31, 2023. Quarterly Highlights •Net sales for the quarter end

PetMeds® Appoints Sandra Y. Campos to its Board of Directors Ms. Campos joins as an independent director, bringing years of executive leadership experience in digital transformations and turnarounds

EXHIBIT 99.1 PetMeds® Appoints Sandra Y. Campos to its Board of Directors Ms. Campos joins as an independent director, bringing years of executive leadership experience in digital transformations and turnarounds DELRAY BEACH, Fla. — May 18, 2023 - PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS), Your Trusted Pet Health Expert™, announced the appointment of Sandra Y. Campos to its Board of Directo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2023 PetMed Express, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File N

DELRAY BEACH, Fla. — April 3, 2023 - PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS), Your Trusted Pet Health Expert™ completed its previously announced acquisition of PetCareRx, Inc., a leading supplier of pet medications, food, and supplies, for t

DELRAY BEACH, Fla. — April 3, 2023 - PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS), Your Trusted Pet Health Expert™ completed its previously announced acquisition of PetCareRx, Inc., a leading supplier of pet medications, food, and supplies, for total consideration of approximately $36 million in an all-cash transaction. The acquisition will expand PetMeds’ overall addressable market from pet m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2023 PetMed Express, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PETS / Petmed Express Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: PetMed Express Inc. Title of Class of Securities: Common Stock CUSIP Number: 716382106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒

Calculation of Registration Fee

EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) PetMed Express, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933

As filed with the Securities and Exchange Commission on February 9, 2023 Registration No.

PETMED EXPRESS, INC. QUARTER ENDED DECEMBER 31, 2022 CONFERENCE CALL TRANSCRIPT FEBRUARY 6, 2023 AT 4:30 P.M. ET

Exhibit 99.1 PETMED EXPRESS, INC. QUARTER ENDED DECEMBER 31, 2022 CONFERENCE CALL TRANSCRIPT FEBRUARY 6, 2023 AT 4:30 P.M. ET Operator Good afternoon everyone and thank you for joining the PetMed Express Third Quarter Earnings Conference Call. I would now like to pass the conference over to our host, Mr. Brian Prenoveau, Investor Relations. Sir, the floor is yours now. Brian Prenoveau Thank you, O

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 o TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

PetMeds® Announces Its Third Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share

Exhibit 99.1 PetMeds® Announces Its Third Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share Delray Beach, Florida, February 6, 2023, PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health ExpertTM, today announced its financial results for its third quarter ended December 31, 2022. Quarterly Highlights •Net sales for the quarter ended December 31, 2022, were $58.

PETS / Petmed Express Inc / ProShare Advisors LLC - PROSHARE ADVISORS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PETMED EXPRESS INC (Name of Issuer) Common Stock (Title of Class of Securities) 716382106 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

Analyst Day January 2023 NASDAQ: PETS 2 Safe Harbor & Non-GAAP Measures This Presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities A

petsinvestordayfinal Analyst Day January 2023 NASDAQ: PETS 2 Safe Harbor & Non-GAAP Measures This Presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning expectations, beliefs plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including statements regarding our environmental and other sustainability plans and goals and potential acquisitions, investments and dispositions.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 19, 2023 PetMed Express,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 19, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2023 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

PetMeds® to Acquire PetCareRx The Acquisition Is Expected to Accelerate Revenue Growth and Expand Addressable Market in a $120 Billion* U.S. Industry

EXHIBIT 99.1 PetMeds® to Acquire PetCareRx The Acquisition Is Expected to Accelerate Revenue Growth and Expand Addressable Market in a $120 Billion* U.S. Industry DELRAY BEACH, Fla. — January 17, 2023 - PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS), Your Trusted Pet Health Expert™, has reached a definitive agreement to acquire PetCareRx, a leading supplier of pet medications, food, and supplies

Agreement and Plan of Merger, dated January 13, 2023, by and among PetMed Express, Inc., Harry Merger Sub, Inc., PetCareRx, Inc., and Jeanette Loeb.*

EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG PETMED EXPRESS, INC., HARRY MERGER SUB, INC., PETCARERX, INC. AND JEANETTE LOEB (AS REPRESENTATIVE OF THE COMPANY EQUITYHOLDERS) January 13, 2023 TABLE OF CONTENTS Page 1. DEFINITIONS 1 1.1 Definitions 1 2. THE MERGER 19 2.1 The Merger 19 2.2 Effective Time 19 2.3 Effect of the Merger 20 2.4 Certificate of Incorporation and Bylaws of the Surviv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 o TRANSITION REPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED

PetMeds® Announces Its Second Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share

Exhibit 99.1 PetMeds? Announces Its Second Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share Delray Beach, Florida, November 7, 2022, PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health ExpertTM, today announced its financial results for its second quarter ended September 30, 2022. Quarterly Highlights ?Net sales for the quarter ended September 30, 2022, were

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

Employment Agreement by and between PetMed Express, Inc. and Christine Chambers

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement, as may be extended and or amended from time to time by mutual consent of the parties hereto (the "Agreement"), dated as of August 03, 2022, is entered into by and between PetMed Express, Inc., a Florida corporation (the "Company"), and Christine Chambers (the "Executive"). WITNESSETH: WHEREAS, the Company desires to e

Restricted Performance Stock Agreement with Christine Chambers

Exhibit 10.3 RESTRICTED PERFORMANCE STOCK AGREEMENT PURSUANT TO PETMED EXPRESS, INC. 2016 EMPLOYEE EQUITY COMPENSATION RESTRICTED STOCK PLAN THIS RESTRICTED PERFORMANCE STOCK AGREEMENT (?Agreement?) is effective the 3rd day of August, 2022 by and between Christine Chambers (the "Participant") and PetMed Express, Inc., a Florida corporation, on behalf of itself, its subsidiaries and affiliates (col

Restricted Stock Agreement with Christine Chambers

Exhibit 10.2 RESTRICTED STOCK AGREEMENT PURSUANT TO PETMED EXPRESS, INC. 2016 EMPLOYEE EQUITY COMPENSATION RESTRICTED STOCK PLAN THIS RESTRICTED STOCK AGREEMENT (?Agreement?) is made this 3rd day of August 2022 by and between Christine Chamber (the "Participant") and PetMed Express, Inc., a Florida corporation, on behalf of itself, its subsidiaries and affiliates (collectively, the "Company") purs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED EXPR

CFO Transition and Separation Agreement by and between PetMed Express, Inc. and Bruce Rosenbloom

Exhibit 10.1 CFO TRANSITION AND SEPARATION AGREEMENT THIS CFO TRANSITION AND SEPARATION AGREEMENT (this ?Agreement?) is dated as of August 2, 2022, by and between Bruce Rosenbloom, an individual whose address is 9600 Savona Winds Drive Delray Beach, FL 33446 (?Executive?), and PetMed Express, Inc., a Florida corporation, whose principal place of business is located at 420 S Congress Ave, Suite 100

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PETMED EXPRESS, INC. QUARTER ENDED JUNE 30, 2022 CONFERENCE CALL TRANSCRIPT JULY 25, 2022 AT 4:30 P.M. ET

Exhibit 99.1 PETMED EXPRESS, INC. QUARTER ENDED JUNE 30, 2022 CONFERENCE CALL TRANSCRIPT JULY 25, 2022 AT 4:30 P.M. ET Operator Welcome to the PetMeds conference call to review the financial results for the first fiscal quarter ended June 30, 2022. At the request of the Company, this conference call is being recorded. Founded in 1996, PetMeds is Your Trusted Pet Health ExpertTM, delivering prescri

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PetMeds® Announces Its First Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share

Exhibit 99.1 PetMeds? Announces Its First Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share Delray Beach, Florida, July 25, 2022, PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health ExpertTM, today announced its financial results for its first quarter ended June 30, 2022. Net sales for the quarter ended June 30, 2022, were $70.2 million, compared to $79.3 mill

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

July 18, 2022

Exhibit 99.1 July 18, 2022 PetMeds? Hires Christine Chambers as Chief Financial Officer Seasoned executive brings a wealth of financial leadership to further accelerate the company?s digital transformation. DELRAY BEACH, Fla. ? PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health Expert, announces the appointment of Christine Chambers as its Chief Financial Officer, effective on August 3,

Offer Letter by and between PetMed Express, Inc. and Christine Chambers

Exhibit 10.1 DELIVERED ELECTRONICALLY Christine Chambers [address] [telephone number] [email address] RE: Offer of Employment Dear Ms. Chambers: We appreciate your interest in PetMed Express, Inc. (the ?Company?). On behalf of the Company, I am pleased to present you with this offer of employment. We are offering you the full-time position of Chief Financial Officer, reporting to Mathew Hulett, CE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

###

Exhibit 99.1 PetMeds? To Announce Its First Quarter Financial Results On July 25, 2022 Delray Beach, Florida, July 11, 2022 - PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the quarter ended June 30, 2022, on Monday, July 25, 2022, at 4:00 P.M. Eastern Time, then at 4:30 P.M. Eastern Time, the Company will host a conference call to review the financial results. To acce

PETMED EXPRESS, INC. 806,805 shares of Common Stock

Filed Pursuant to Rule 424(b)(3) and (c) Registration Number 333-218917 PROSPECTUS SUPPLEMENT NO.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(

Description of Securities.*

Exhibit 4.2 DESCRIPTION OF THE COMPANY?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of the common stock, $0.001 par value per share (the ?Common Stock?), of PetMed Express, Inc., a Florida corporation (the ?Company?), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28827 PETMED EXPRESS, INC. (Exact n

Subsidiaries of Registrant*

Exhibit 21.1 SUBSIDIARIES OF PETMED EXPRESS, INC. PetMed Express, Inc. directly owns all of the outstanding interests in the following subsidiaries: Southeastern Veterinary Exports, Inc., a Florida Corporation First Image Marketing, Inc., a Florida Corporation Global Veterinary Supply, Inc., a Florida Corporation 420 South Congress Avenue LLC, a Florida Limited Liability Company

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File Nu

PETMED EXPRESS, INC. QUARTER AND YEAD ENDED MARCH 31, 2022 CONFERENCE CALL TRANSCRIPT MAY 9, 2022 AT 4:30 P.M. ET

Exhibit 99.1 PETMED EXPRESS, INC. QUARTER AND YEAD ENDED MARCH 31, 2022 CONFERENCE CALL TRANSCRIPT MAY 9, 2022 AT 4:30 P.M. ET Operator Welcome to PetMeds? conference call to review the financial results for the fourth quarter and fiscal year end March 31, 2022. During the presentation all participants will be in a listen only mode. Afterwards we will conduct a question-and- answer session, at tha

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File Nu

PetMeds® Hires Pet-Industry Veteran into Pivotal Leadership Role In her new role as VP of Product Management, Carolyn Carden will scale PetMeds’ product portfolio, including its rapidly growing telemedicine business

Exhibit 99.1 PetMeds? Hires Pet-Industry Veteran into Pivotal Leadership Role In her new role as VP of Product Management, Carolyn Carden will scale PetMeds? product portfolio, including its rapidly growing telemedicine business DELRAY BEACH, Fla., May 9, 2022 (GLOBE NEWSWIRE) ? PetMed Express, Inc. (NASDAQ: PETS), Your Most Trusted Pet Health Expert, today announces the appointment of former Petc

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File Nu

PetMeds® Announces Its Fourth Quarter and Fiscal Year End Financial Results Declares a Quarterly Dividend of $0.30 Per Share

Exhibit 99.1 PetMeds? Announces Its Fourth Quarter and Fiscal Year End Financial Results Declares a Quarterly Dividend of $0.30 Per Share Delray Beach, Florida, May 9, 2022, PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter and fiscal year ended March 31, 2022. Net sales for the quarter ended March 31, 2022, were $66.0 million, compared to $71.7 million for

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File Nu

###

Exhibit 99.1 PetMeds? To Announce Its Fourth Quarter Financial Results On May 9, 2022 Delray Beach, Florida, May 2, 2022 - PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the quarter and year ended March 31, 2022, on Monday, May 9, 2022, at 4:00 P.M. Eastern Time, then at 4:30 P.M. Eastern Time, the Company will host a conference call to review the financial results. To

New agreement with the fastest-growing veterinary telehealth and pet-care marketplace provides 24/7 access to over 70,000 veterinarians for PetMeds®’ millions of pet parents.

Exhibit 99.1 PetMeds® Announces Exclusive Partnership with Vetster for Pet Telemedicine New agreement with the fastest-growing veterinary telehealth and pet-care marketplace provides 24/7 access to over 70,000 veterinarians for PetMeds®’ millions of pet parents. DELRAY BEACH, FL April 19, 2022— PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health Expert, today announced an exclusive partne

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 19, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PETMED EXPRESS WELCOMES DIANA GARVIS PURCEL TO ITS BOARD OF DIRECTORS

Exhibit 99.1 PETMED EXPRESS WELCOMES DIANA GARVIS PURCEL TO ITS BOARD OF DIRECTORS Delray Beach, Florida, March 28, 2022 ? PetMed Express, Inc. (NASDAQ: PETS), is pleased to announce that Diana Garvis Purcel has been appointed to the PetMed Express, Inc. Board of Directors as a new independent director, effective April 4, 2022. Ms. Purcel will also serve as the next Chair of the Board?s Audit Comm

PETS / Petmed Express Inc / ProShare Advisors LLC - PROSHARE ADVISORS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PETMED EXPRESS INC (Name of Issuer) Common Stock (Title of Class of Securities) 716382106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X]

PETS / Petmed Express Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: PetMed Express Inc. Title of Class of Securities: Common Stock CUSIP Number: 716382106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 24, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

PETMED EXPRESS, INC. QUARTER ENDED DECMBER 31, 2021 CONFERENCE CALL TRANSCRIPT JANUARY 24, 2022 AT 4:30 P.M. ET

Exhibit 99.1 PETMED EXPRESS, INC. QUARTER ENDED DECMBER 31, 2021 CONFERENCE CALL TRANSCRIPT JANUARY 24, 2022 AT 4:30 P.M. ET Operator Welcome to the PetMeds Conference Call to Review the Financial Results for the Third Fiscal Quarter ended on December 31, 2021. At the request of the Company, this conference call is being recorded. Founded in 1996, PetMeds is America?s Most Trusted Pet Pharmacy, de

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 24, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

PetMeds® Announces Its Third Fiscal Quarter Financial Results and Its Quarterly Dividend of $0.30 Per Share

Exhibit 99.1 PetMeds? Announces Its Third Fiscal Quarter Financial Results and Its Quarterly Dividend of $0.30 Per Share Delray Beach, Florida, January 24, 2022, PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter ended December 31, 2021. Net sales for the quarter ended December 31, 2021, were $60.7 million, compared to $65.9 million for the quarter ended Dece

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 18, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

###

Exhibit 99.1 PetMeds? To Announce Its Third Quarter Financial Results On January 24, 2022 Delray Beach, Florida, January 18, 2022 - PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the quarter ended December 31, 2021, on Monday, January 24, 2022, at 4:00 P.M. Eastern Time, then at 4:30 P.M. Eastern Time, the Company will host a conference call to review the financial res

PetMeds® Appoints Three New Key Executives Strategic hires will be instrumental to the company’s digital transformation and future growth.

Exhibit 99.1 PetMeds? Appoints Three New Key Executives Strategic hires will be instrumental to the company?s digital transformation and future growth. DELRAY BEACH, Florida, January 10, 2022. ? PetMed Express, Inc. (NASDAQ: PETS), America's Most Trusted Pet Pharmacy?, today announced the addition of three new executives to the company. These key hires are an integral part of PetMeds? digital tran

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED

PETMED EXPRESS, INC. QUARTER ENDED SEPTEMBER 30, 2021 CONFERENCE CALL TRANSCRIPT OCTOBER 25, 2021 AT 4:30 P.M. ET

Exhibit 99.1 PETMED EXPRESS, INC. QUARTER ENDED SEPTEMBER 30, 2021 CONFERENCE CALL TRANSCRIPT OCTOBER 25, 2021 AT 4:30 P.M. ET Operator Welcome to the PetMeds Conference Call to Review the Financial Results for the Second Fiscal Quarter ended on September 30, 2021. At the request of the Company, this conference call is being recorded. Founded in 1996, PetMeds is America?s Most Trusted Pet Pharmacy

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 25, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

Financial Statements and Exhibits, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 25, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

PETMED EXPRESS ANNOUNCES ITS SECOND QUARTER FINANCIAL RESULTS AND ITS QUARTELY DIVIDEND OF $0.30 PER SHARE

Exhibit 99.1 PETMED EXPRESS ANNOUNCES ITS SECOND QUARTER FINANCIAL RESULTS AND ITS QUARTELY DIVIDEND OF $0.30 PER SHARE Delray Beach, Florida, October 25, 2021, PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter ended September 30, 2021. Net sales for the quarter ended September 30, 2021 were $67.4 million, compared to $75.4 million for the quarter ended Sept

###

Exhibit 99.1 PETMED EXPRESS TO ANNOUNCE ITS SECOND QUARTER FINANCIAL RESULTS ON OCTOBER 25, 2021 Delray Beach, Florida, October 18, 2021 - PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the quarter ended September 30, 2021 on Monday, October 25, 2021 at 4:00 P.M. Eastern Time, then at 4:30 P.M. Eastern Time, the Company will host a conference call to review the financi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission Fi

Restricted Stock Agreement with Mathew N. Hulett (incorporated by reference to Exhibit 10.2 to our Form 8-K filed August 30, 2021).

Exhibit 10.2 RESTRICTED STOCK AGREEMENT PURSUANT TO PETMED EXPRESS, INC. 2016 EMPLOYEE EQUITY COMPENSATION RESTRICTED STOCK PLAN THIS RESTRICTED STOCK AGREEMENT (?Agreement?) is effective the 30th day of August, 2021 by and between Mathew Hulett (the "Participant") and PetMed Express, Inc., a Florida corporation, on behalf of itself, its subsidiaries and affiliates (collectively, the "Company") pu

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2021 PETMED EXPRESS, INC. (Exact name of Registrant as specified in its charter) Commission file number: 000-28827 Florida 65-0680967 (State or other jurisdiction of incorp

Employment Agreement with Mathew Hulett dated August 25, 2021

EX-10.1 2 ex279895.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement, as may be extended and or amended from time to time by mutual consent of the parties hereto (the "Agreement"), dated as of August 25, 2021, is entered into by and between PetMed Express, Inc., a Florida corporation (the "Company"), and Mathew Hulett (the "Executive"). WITNESSETH: WH

Restricted Performance Stock Agreement with Mathew N. Hulett (incorporated by reference to Exhibit 10.3 to our Form 8-K filed August 30, 2021).

Exhibit 10.3 RESTRICTED PERFORMANCE STOCK AGREEMENT PURSUANT TO PETMED EXPRESS, INC. 2016 EMPLOYEE EQUITY COMPENSATION RESTRICTED STOCK PLAN THIS RESTRICTED PERFORMANCE STOCK AGREEMENT (?Agreement?) is effective the 30th day of August, 2021 by and between Mathew Hulett (the "Participant") and PetMed Express, Inc., a Florida corporation, on behalf of itself, its subsidiaries and affiliates (collect

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PETMED EXPRESS WELCOMES JODI WATSON AND PETER COBB TO ITS BOARD OF DIRECTORS

Exhibit 99.1 PETMED EXPRESS WELCOMES JODI WATSON AND PETER COBB TO ITS BOARD OF DIRECTORS Delray Beach, Florida, August 2, 2021 - PetMed Express, Inc. (NASDAQ: PETS) is delighted to report that Jodi Watson and Peter Cobb have been elected to the PetMed Express, Inc. Board of Directors as new independent directors. Ms. Watson is a highly accomplished Senior Executive with more than 20 years of prog

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED EXPR

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PETMED EXPRESS, INC. QUARTER ENDED JUNE 30, 2021 CONFERENCE CALL TRANSCRIPT JULY 26, 2021 AT 8:30 A.M. ET

Exhibit 99.1 PETMED EXPRESS, INC. QUARTER ENDED JUNE 30, 2021 CONFERENCE CALL TRANSCRIPT JULY 26, 2021 AT 8:30 A.M. ET Coordinator: Welcome to the 1-800-PetMeds Conference Call to Review the Financial Results of the First Fiscal Quarter ended on June 30, 2021. At the request of the Company, this conference call is being recorded. Founded in 1996, 1-800-PetMeds is America's most trusted pet pharmac

Financial Statements and Exhibits, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

PETMED EXPRESS, INC. D/B/A 1-800-PETMEDS ANNOUNCES ITS FIRST QUARTER FINANCIAL RESULTS AND A QUARTERLY DIVIDEND OF $0.30 PER SHARE

EX-99.1 2 ex267426.htm EXHIBIT 99.1 Exhibit 99.1 PETMED EXPRESS, INC. D/B/A 1-800-PETMEDS ANNOUNCES ITS FIRST QUARTER FINANCIAL RESULTS AND A QUARTERLY DIVIDEND OF $0.30 PER SHARE Delray Beach, Florida, July 26, 2021 - PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2021. Net sales for the quarter ended June 30, 2021 were $79.3 million

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

###

Exhibit 99.1 PETMED EXPRESS D/B/A 1-800-PETMEDS TO ANNOUNCE ITS FIRST QUARTER FINANCIAL RESULTS ON JULY 26, 2021 Delray Beach, Florida, July 19, 2021 - PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the quarter ended June 30, 2021 on Monday, July 26, 2021 at 8:00 A.M. Eastern Time, then at 8:30 A.M. Eastern Time, the Company will host a conference call to review the fi

Letter Agreement dated July 3, 2021 between PetMed Express, Inc. and Bruce S. Rosenbloom

Exhibit 10.1 Bruce, As discussed, all of us on the board are really appreciative of your offer to step into the interim CEO and President role when Mendo leaves the business at the end of July. We agree that this appointment will be well received by internal and external stakeholders, and that you are best positioned to take on many of Mendo?s responsibilities until such time as the new CEO is app

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 3, 2021 PETMED EXPRESS, INC. (Exact name of Registrant as specified in its charter) Commission file number: 000-28827 Florida 65-0680967 (State or other jurisdiction of incorpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2021 PETMED EXPRESS, INC. (Exact name of Registrant as specified in its charter) Commission file number: 000-28827 Florida 65-0680967 (State or other jurisdiction of incorpor

CEO Separation Agreement and General Release, dated June 11, 2021, between PetMed Express, Inc. and Menderes Akdag

EX-10.1 2 ex257246.htm EXHIBIT 10.1 Exhibit 10.1 CEO SEPARATION AGREEMENT AND GENERAL RELEASE THIS CEO SEPARATION AGREEMENT AND GENERAL RELEASE (this “Agreement”) is dated as of June 11, 2021, by and between Menderes Akdag, an individual whose address is 7136 NE 8 Drive, Boca Raton, FL 33487 (“Executive”), and PetMed Express, Inc., a Florida corporation, whose principal place of business is locate

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File N

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File N

Subsidiaries of Registrant*

EX-21.1 2 ex252271.htm EXHIBIT 21.1 Exhibit 21.1 SUBSIDIARIES OF PETMED EXPRESS, INC. PetMed Express, Inc. directly owns all of the outstanding interests in the following subsidiaries: Southeastern Veterinary Exports, Inc., a Florida Corporation First Image Marketing, Inc., a Florida Corporation Global Veterinary Supply, Inc., a Florida Corporation 420 South Congress Avenue LLC, a Florida Limited

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-28827 PETMED EXPRESS, INC. (Exact n

PETMED EXPRESS, INC. QUARTER AND YEAR ENDED MARCH 31, 2021 CONFERENCE CALL TRANSCRIPT MAY 3, 2021 AT 8:30 A.M. ET

EX-99.1 2 ex246826.htm EXHIBIT 99.1 Exhibit 99.1 PETMED EXPRESS, INC. QUARTER AND YEAR ENDED MARCH 31, 2021 CONFERENCE CALL TRANSCRIPT MAY 3, 2021 AT 8:30 A.M. ET Coordinator: Welcome to the PetMed Express, Incorporated Doing Business as 1-800-PetMeds Conference Call to review the financial results for the fourth fiscal quarter and fiscal year ended on March 31, 2021. At the request of the Company

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File Nu

Financial Statements and Exhibits, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File Nu

PETMED EXPRESS, INC. D/B/A 1-800-PETMEDS ANNOUNCES ITS FOURTH QUARTER AND FISCAL YEAR END FINANCIAL RESULTS AND INCREASES ITS QUARTERLY DIVIDEND TO $0.30 PER SHARE 8.8% Increase in Fiscal 2021 Sales 18.4% Increase in Fiscal 2021 Net Income 9.7% Incre

Exhibit 99.1 PETMED EXPRESS, INC. D/B/A 1-800-PETMEDS ANNOUNCES ITS FOURTH QUARTER AND FISCAL YEAR END FINANCIAL RESULTS AND INCREASES ITS QUARTERLY DIVIDEND TO $0.30 PER SHARE 8.8% Increase in Fiscal 2021 Sales 18.4% Increase in Fiscal 2021 Net Income 9.7% Increase in Fiscal 2021 Reorder Sales Delray Beach, Florida, May 3, 2021 - PetMed Express, Inc. (NASDAQ: PETS) today announced its financial r

###

EX-99.1 2 ex243657.htm EXHIBIT 99.1 Exhibit 99.1 PETMED EXPRESS D/B/A 1-800-PETMEDS TO ANNOUNCE ITS FISCAL YEAR END FINANCIAL RESULTS ON MAY 3, 2021 Delray Beach, Florida, April 26, 2021 - PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the fiscal year ended March 31, 2021 on Monday, May 3, 2021 at 8:00 A.M. Eastern Time, then at 8:30 A.M. Eastern Time, Menderes Akdag,

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission File

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission F

CORPORATE GOVERNANCE GUIDELINES (Amended and Restated Effective February 15, 2021)

EX-99.2 3 ex227630.htm EXHIBIT 99.2 Exhibit 99.2 CORPORATE GOVERNANCE GUIDELINES (Amended and Restated Effective February 15, 2021) These Corporate Governance Guidelines (“Guidelines”) of PetMed Express, Inc. ("Company") are intended as a component of the flexible governance framework within which the Board of Directors of the Company (the "Board"), assisted by its committees, directs the affairs

CORPORATE GOVERNANCE AND NOMINATING COMMITTEE CHARTER (Amended and Restated Effective February 15, 2021)

EX-99.1 2 ex227629.htm EXHIBIT 99.1 Exhibit 99.1 CORPORATE GOVERNANCE AND NOMINATING COMMITTEE CHARTER (Amended and Restated Effective February 15, 2021) I. PURPOSE The primary purposes of the Corporate Governance and Nominating Committee (“Committee”) of PetMed Express, Inc. (“Company”) are to: (1) identify, screen and review individuals qualified to serve as directors of the Company and recommen

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission F

PETMED EXPRESS, INC. 320,335 shares of Common Stock

Filed Pursuant to Rule 424(b)(3) and (c) Registration Number 333-218917 PROSPECTUS SUPPLEMENT NO.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2021 PetMed Express, Inc. (Exact name of registrant as specified in its charter) Florida 000-28827 65-0680967 (State or other jurisdiction of incorporation) (Commission F

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: PetMed Express Inc. Title of Class of Securities: Common Stock CUSIP Number: 716382106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒

Quarterly Report - FORM 10-Q

UNITED STATES securities and exchange commission Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-28827 PETMED

PETMED EXPRESS, INC. QUARTER ENDED DECEMBER 31, 2020 CONFERENCE CALL TRANSCRIPT JANUARY 19, 2021 AT 8:30 A.M. ET

EX-99.1 2 ex221607.htm EXHIBIT 99.1 Exhibit 99.1 PETMED EXPRESS, INC. QUARTER ENDED DECEMBER 31, 2020 CONFERENCE CALL TRANSCRIPT JANUARY 19, 2021 AT 8:30 A.M. ET Coordinator: Welcome to the PetMed Express Inc. doing business as 1-800-PetMeds conference call to review the financial results for the third fiscal quarter for the quarter ended on December 31, 2020. At the request of the company, this c